10-Q: DataMeds AI Faces Liquidity Crisis Despite Debt Gain

DataMeds AI reported a net income for the quarter driven by debt extinguishment, but faces substantial doubt about its ability to continue as a going concern due to significant working capital deficit and upcoming debt maturities.

Summary

• DataMeds AI, Inc. (formerly Wellgistics Health, Inc.) reported a net income of $10.5 million for the three months ended September 30, 2026, a significant turnaround from a net loss of $34.3 million in the prior year period. This income was largely driven by a non-cash gain of $19.1 million from the extinguishment of debt related to the settlement with Wellgistics, LLC sellers.
• However, for the nine months ended September 30, 2026, the company incurred a net loss of $15.6 million. As of September 30, 2026, the company had cash and cash equivalents of $476,598 and a working capital deficit of $31.3 million.
• Significant debt obligations, including $20.3 million under the New Notes maturing in May 2027, raise substantial doubt about the company's ability to continue as a going concern within one year.
• Revenues for the nine months ended September 30, 2026, decreased by 72.3% to $6.0 million compared to $21.7 million in the prior year, primarily due to a sharp decline in distribution revenues from Wellgistics, LLC, attributed to liquidity constraints.
• The company completed the acquisition of Helomics Corporation and the Healthstar asset acquisition during the period.
• The company regained compliance with Nasdaq's minimum bid price and minimum stockholders equity requirements, though ongoing compliance is subject to future periodic reports.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative score due to significant ongoing liquidity concerns, substantial accumulated deficit, and a going concern warning, despite a recent net income driven by debt extinguishment gains.

Positives

• Reported a net income of $10.5 million for the three months ended September 30, 2026, a significant improvement from a net loss of $34.3 million in the prior year period.
• Achieved a substantial non-cash gain of $19.1 million from the extinguishment of debt related to the settlement with Wellgistics, LLC sellers.
• Gross profit for the three months ended September 30, 2026, increased by 87.0% to $431,880, with gross margin improving to 16.2% from 7.7%.
• Regained compliance with Nasdaq's minimum bid price requirement.
• Regained compliance with Nasdaq's minimum stockholders equity requirement as of October 19, 2026, although ongoing compliance is monitored.

Negatives

• Incurred a net loss of $15.6 million for the nine months ended September 30, 2026.
• Significant working capital deficit of $31.3 million as of September 30, 2026.
• Substantial doubt exists about the company's ability to continue as a going concern within one year due to liquidity constraints and upcoming debt maturities.
• Revenues for the nine months ended September 30, 2026, decreased by 72.3% to $6.0 million compared to $21.7 million in the prior year.
• Distribution revenues from Wellgistics, LLC significantly declined due to liquidity constraints.
• Outstanding debt obligations include $20.3 million under the New Notes maturing in May 2027.
• The company has a substantial accumulated deficit of $126.5 million as of September 30, 2026.
• Material weaknesses in internal control over financial reporting were identified.

Risks

• Substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.
• The Company does not currently have sufficient cash to repay its obligations as they become due, including $20.3 million under the New Notes maturing on May 27, 2027.
• The Company's common stock may be subject to delisting from The Nasdaq Capital Market if it fails to maintain compliance with continued listing requirements.
• The Company has material weaknesses in its internal control over financial reporting, including control environment, risk assessment, control activities, information and communication, and monitoring.
• The Company's distribution business experienced a significant decline in revenue due to liquidity constraints, impacting its ability to procure and fulfill product orders.
• The Company's pharmacy operations purchase substantially all of their pharmaceutical products from a single wholesale vendor, and the loss of this vendor or a disruption in its supply could have a material adverse effect.
• The REBOOT License Agreement includes a contingent consideration liability of $953,906, which could increase if the market value of the issued shares declines.
• The Company has received demand letters from various vendors for approximately $4.4 million in aggregate, of which $1.6 million is not currently recorded as a liability.

Future Outlook

The company is actively pursuing additional sources of capital, including equity financing, debt arrangements, and strategic transactions to address its liquidity position and going concern uncertainties. However, there is no assurance that such financing or transactions will be available on acceptable terms or at all. The company's ability to maintain Nasdaq listing is also a key future consideration.

Management Comments

• Management is pursuing multiple initiatives to address the Company's liquidity position and the substantial doubt about its ability to continue as a going concern.
• Management evaluated the decline in the distribution business and believes the Company has plans in place to address its underlying causes.
• Management has implemented or is in the process of implementing measures to remediate material weaknesses in internal control over financial reporting.

Industry Context

StockSavvy.ai notes that DataMeds AI operates in the highly competitive and regulated healthcare and pharmaceutical sectors. The company's focus on a 'micro health ecosystem' with integrated technology, pharmacy, and distribution services aims to address challenges like medication adherence and patient access. The reported revenue decline in distribution, attributed to liquidity issues, is a significant concern in an industry where reliable supply chains are critical. The company's efforts to pivot towards higher-margin pharmacy retail and technology services are strategically aligned with industry trends towards digital health solutions and patient-centric care.

Comparison to Industry Standards

• The company's revenue decline in its distribution segment (Wellgistics, LLC) is concerning, as industry-standard practice for pharmaceutical distributors involves robust inventory management and reliable fulfillment, which are hampered by liquidity constraints.
• The significant increase in pharmacy retail sales is a positive indicator, as the pharmacy sector generally sees consistent demand, but the company's ability to scale this segment profitably against larger players remains a key benchmark.
• The company's reported net income for the quarter, driven by debt extinguishment, is not a sustainable industry standard for operational performance. Sustainable growth typically comes from core business operations, not one-off financial gains.
• The ongoing struggle with Nasdaq listing compliance, particularly the minimum stockholders equity requirement, highlights a deviation from the financial stability expected of publicly traded companies in the healthcare sector.
• The company's reported net loss for the nine-month period and substantial accumulated deficit are contrary to the profitability and financial health generally expected from established players in the pharmaceutical services industry.

Legal Proceedings

• Blythe Global Advisors, LLC arbitration for breach of contract and breach of personal guaranty, claiming $377,947 in unpaid accounting services.
• Lawsuit filed by DataMeds AI subsidiaries against Blythe Global Advisors, LLC for improper UCC-1 filings, tortious interference, slander of title, and state RICO violations.
• Lawsuit filed by Lifsa Drugs LLC against Wellgistics, LLC for approximately $420,460 in unpaid pharmaceutical products.
• Strategic EP filed suit against the Company seeking repayment of its $250,000 promissory note, plus accrued interest, fees, and costs, totaling approximately $272,122.

Related Party Transactions

• Accounts payable to Scietech, LLC, where a significant investor is the spouse of a director, was $25,500 as of September 30, 2026.
• Advances of $1,112,927 due from Tollo Health, a related party through Interim Co-Chief Executive Officer Gerald Commissiong, for working capital.
• Consulting fees of $278,814 incurred to Fortitude Advisors, LLC, also related through Gerald Commissiong, for Chief Business Officer services during the nine months ended September 30, 2026.

Stakeholder Impact

• Shareholders face continued uncertainty regarding the company's going concern status and potential delisting from Nasdaq.
• Creditors and lenders face increased risk due to the company's liquidity challenges and significant debt obligations.
• Employees may experience uncertainty regarding job security given the company's financial precariousness and ongoing restructuring efforts.
• Suppliers may face delays or non-payment of outstanding invoices, as evidenced by vendor demand letters and the company's reliance on equity to settle obligations.

Next Steps

• Management is actively pursuing additional sources of capital, including equity financing, debt arrangements, and strategic transactions.
• The company must continue to monitor its compliance with Nasdaq listing requirements, particularly the minimum stockholders equity requirement.
• The company is in the process of integrating Helomics and Healthstar into its internal control over financial reporting.
• Management is implementing measures to remediate material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The company's severe liquidity issues, substantial accumulated deficit, and explicit going concern warning, despite a recent quarter's net income driven by non-operational gains, present significant risks. The sharp decline in revenues and ongoing operational challenges, coupled with the potential for Nasdaq delisting, outweigh the positives. Investors should consider divesting or avoiding investment until a sustainable path to profitability and financial stability is clearly demonstrated.

Keywords

DataMeds AI, 10-Q Filing, Quarterly Report, Financial Statements, Liquidity, Going Concern, Debt Extinguishment, Helomics Acquisition